SpliceBio has licenced its intein technlogy to Roche’s gene therapy subsidiary Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease.
https://european-biotechnology.com/wp-content/uploads/2024/04/splicebio.jpg330900Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-10-18 08:40:122024-07-09 13:13:21SpliceBio has made up a US $216m alliance with Spark Therapeutics